# Applicant

Focus Diagnostics, Inc. 11331 Valley View Street Cypress, California 90630 USA

Establishment Registration No. Contact Person

2023365

Tara Viviani tel 714.822.2115 fax 714.822.3898 tviviani@focusdx.com

November 12, 2010

Simplexa™ Flu A/B & RSV

Summary Date Proprietary Name Generic Name Classification Predicate Devices

Respiratory Viral Panel

Class II, Special Controls

# Intended Use

The Focus Diagnostics Simplexa™ Flu A/B & RSV assay is intended for use on the 3M Integrated Cycler insrent oreviqualtativetectionisrinationfenzviuinlenzav and respiratory syncytial virus (RSV) RNA in nasopharyngeal swabs (NPS) from human patients with signs and symptoms of respiratory tract infection in conjunction with clinical and epidemiological risk frThis sorsnnheifal za RSV viral infections in humans and is not intended to detect influenza C.

Negative results do not preclude influenza virus or RSV infection and should not be used as the sole basis for treatment or other patient management decisions.

Performance characteristics for influenza A were established during the 2010 influenza season when 2009 H1N1 influenza was the predominant influenza A virus in circulation. When other influenza A viruses are emerging, performance characteristics may vary.

If infection with a novel Influenza A virus is suspected based on current clinical and epidemiological screening criteria recommended by public health authorities, specimens should be collected with appropriate infection control precautions for novel virulent Influenza viruses and sent to state or local health department for testing. Viral culture should not be attempted in these cases unless a BSL $^ { 3 + }$ EP facility is available to receive and culture specimens.

# Device Description

The test is a real-time RT-PCR amplification and detection system that utilies a bi-functional fuorescent probe-primer for the detection and differentiation of human influenza A virus RNA, human influenza B virus RNA and respiratory syncytial virus RNA in nasopharyngeal swabs (NPS).The assay is composed of two principal steps:(1) extraction of RNA from patient specimens, (2) A bi-functional fluorescent probe-primer is used together with a reverse primer to amplify a specific target or each analyte and the RNA internal control.Theassay provides three results;conserved regions ofinfluenz A viruses ari gene), influenza B viruses (matrix gene) andRSV (M gene) are targeted to identify these viruses in the specimen. An RNA internal control is used to monitor the extraction process and to detect RT-PCR inhibition.

The 3M Integrated Cycler is a rapid real-time Polymerase Chain Reaction thermocycler used for the identification of nucleic acid from prepared biological samples. The instrument utilizes disk media to contain and to process samples.The instrument uses real time flourometric detection to identify targets within the sample wells. The instrument is controled by an external computer running the Integrated Cycler Studio Software.

Predicate Device Information   

<table><tr><td rowspan=1 colspan=1>Trade Name / Method</td><td rowspan=1 colspan=1>510(k)submitter</td><td rowspan=1 colspan=1>510(k)number</td><td rowspan=1 colspan=1>DecisionDate*</td><td rowspan=1 colspan=1>Panel</td><td rowspan=1 colspan=1>ProductCode(s)</td></tr><tr><td rowspan=1 colspan=1>proFlu+</td><td rowspan=1 colspan=1>Prodesse</td><td rowspan=1 colspan=1>K092500,K081030,K073029</td><td rowspan=1 colspan=1>08/20/200905/02/200801/04/2008</td><td rowspan=1 colspan=1>Microbiology(83)</td><td rowspan=1 colspan=1>OCC</td></tr></table>

# Comparison to Predicate

<table><tr><td colspan="1" rowspan="1">ItemName</td><td colspan="1" rowspan="1">Device                  4Simplexa™ Flu A/B &amp; RSV</td><td colspan="1" rowspan="1">PredicateProFlu+</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">The Focus Diagnostics SimplexaFlu A/B &amp; RSV assay is intended foruse on the 3M Integrated Cyclerinstrument for the in vitro qualitativedetection  and  discrim ination  ofinfluenza A virus, influenza B virus,and respiratory syncytial virus (RSV)RNA in nasopharyngeal swabs (NPS)from human patients with signs andsymptoms of respiratory tract infectionin conjunctionwithclinical andepidemiological risk factors. This testis intended for use as an aid in thedifferential diagnosis of influenza A,influenza B, and RSV viral infectionsin humans and is not intended todetect influenza C.Negative results do notprecludeinfluenza virus or RSV infection andshould not be used as the sole basisfor treatment or other patientmanagement decisions.Performance    characteristics    forinfluenza A were established duringthe 2010 influenza season when 2009H1N1 influenza was the predominantinfluenza A virus in circulation. Whenother  influenza A viruses  are</td><td colspan="1" rowspan="1">The ProFluT+ Assay is a multiplexReal-Time PCR (RT-PCR) in vitrodiagnostic test for the rapid andqualitative        detection        anddiscrimination of Influenza A Virus,Influenza B Virus, and RespiratorySyncytial Virus (RSV) nucleic acidsisolated     and    purified    fromnasopharyngeal (NP) swab specimensobtained from symptomatic patients.This test is intended for use to aid inthe differential diagnosis of InfluenzaA, Influenza B and RSV viral infectionsin humans and is not intended todetect Influenza C.Negative results do not precludeinfluenza or RSV virus infection andshould not be used as the sole basisfor treatment or other managementdecisions. It is recommended thatnegative RSV results be confirmed byculture. Performance characteristicsfor Influenza A Virus were establishedwhen Influenza AH3 and A/H1 werethe predominant Influenza A viruses incirculation. When other Influenza Aviruses are emerging, performancecharacteristics may vary.</td></tr><tr><td colspan="1" rowspan="1">ItemName</td><td colspan="1" rowspan="1">DeviceSimplexa™ Flu A/B &amp; RSV</td><td colspan="1" rowspan="1">PredicateProFlu+</td></tr><tr><td colspan="1" rowspan="1">′</td><td colspan="1" rowspan="1">emerging, performance characteristicsmay vary.If infection with a novel Influenza Avirus is suspected based on currentclinical and epidemiological screeningcriteria recommended by public healthauthorities, specimens should becollected with appropriate infectioncontrol precautions for novel virulentInfluenza viruses and sent to state orlocal health department for testing.Viral culture should not be attemptedin these cases unless a BSL 3+ facilityis available to receive and culturespecimens.</td><td colspan="1" rowspan="1">If infection with a novel Influenza Avirus is suspected based on currentclinical and epidemiological screeningcriteria recommended by public healthauthorities, specimens should becollected with appropriate infectioncontrol precautions for novel virulentInfluenza viruses and sent to state orlocal health department for testing.Viral culture should not be attemptedin these cases unless a BSL 3+ facilityis available to receive and culturespecimens.</td></tr><tr><td colspan="1" rowspan="1">Assay Targets</td><td colspan="1" rowspan="1">Influenza A, Influenza B, RSV</td><td colspan="1" rowspan="1">Influenza A, Influenza B, RSV</td></tr><tr><td colspan="1" rowspan="1">Sample Types</td><td colspan="1" rowspan="1">NPS</td><td colspan="1" rowspan="1">NPS</td></tr><tr><td colspan="1" rowspan="1">ExtractionMethods</td><td colspan="1" rowspan="1">Roche MagNA Pure LC Total NucleicAcid Isolation Kit,Biomérieux NucliSENS easyMAG</td><td colspan="1" rowspan="1">Roche MagNA Pure LC Total NucleicAcid Isolation Kit,Biomérieux NucliSENS easyMAG</td></tr><tr><td colspan="1" rowspan="1">AssayMethodology</td><td colspan="1" rowspan="1">PCR-based system for detecting thepresence / absence of viral RNA inclinical specimens</td><td colspan="1" rowspan="1">PCR-based system for detecting thepresence / absence of viral DNA/RNAin clinical specimens</td></tr><tr><td colspan="1" rowspan="1">DetectionTechniques</td><td colspan="1" rowspan="1">Multiplex assay using differentreporter dyes for each target.</td><td colspan="1" rowspan="1">Multiplex assay using differentreporter dyes for each target.</td></tr><tr><td colspan="1" rowspan="1">Influenza AViral Target</td><td colspan="1" rowspan="1">Well conserved region of the matrixgene</td><td colspan="1" rowspan="1">Matrix gene</td></tr><tr><td colspan="1" rowspan="1">Influenza BViral Target</td><td colspan="1" rowspan="1">Well conserved region of the matrixgene</td><td colspan="1" rowspan="1">Non-structural NS1 and NS2</td></tr><tr><td colspan="1" rowspan="1">RespiratorySyncytial ViralTarget</td><td colspan="1" rowspan="1">M gene</td><td colspan="1" rowspan="1">Polymerase</td></tr></table>

# Reproducibility:

Tvatiay. io w y t day.One site performed the extraction using the MagNA Pure LC Total Nucleic Acid Isolation Kit; two sites performed the extraction step using the Biomérieux NucliSENS easyMAG.Combined results for al sites are summarized below.

Influenza $\mathsf { A } =$ Total $\% C V$ of 0.8 to 2.1   
Influenza $\mathsf { B } =$ Total $\% 0 v$ of 0.5 to 6.8   
RSV Total $\% C V$ of 2.1 to 4.5

Limit of Detection   

<table><tr><td rowspan=1 colspan=1>Viral Strain</td><td rowspan=1 colspan=1>LoD MagNA Pureextraction (TCIDsd/mL)</td><td rowspan=1 colspan=1>LoD NucliSENS easyMAGextraction (TCID5o/mL)</td></tr><tr><td rowspan=1 colspan=1>Influenza APR/8/34 (H1N1)</td><td rowspan=1 colspan=1>1.0 x10^{2</td><td rowspan=1 colspan=1>1.0 x10^2</td></tr><tr><td rowspan=1 colspan=1>Influenza A/Hong Kong/8/68 (H3N2)</td><td rowspan=1 colspan=1>1.0 x10</td><td rowspan=1 colspan=1>1.0 x10</td></tr><tr><td rowspan=1 colspan=1>Influenza B/Great Lakes/1739/54</td><td rowspan=1 colspan=1>1.0 x10}$</td><td rowspan=1 colspan=1>5.0 x10 }$</td></tr><tr><td rowspan=1 colspan=1>Influenza B/Malaysia/2506/2004</td><td rowspan=1 colspan=1>1.0 x10&#x27;</td><td rowspan=1 colspan=1>1.0 x10&#x27;</td></tr><tr><td rowspan=1 colspan=1>RSV A2</td><td rowspan=1 colspan=1>1.0 x10}$</td><td rowspan=1 colspan=1>1.0 x10r}$</td></tr><tr><td rowspan=1 colspan=1>RSV B1</td><td rowspan=1 colspan=1>1.0 x10}$</td><td rowspan=1 colspan=1>5.0 x10 }$</td></tr></table>

# Analytical Reactivity

<table><tr><td rowspan=1 colspan=1>Viral Strain</td><td rowspan=1 colspan=1>Lowest Concentration Detected(TCID5o/mL)</td><td rowspan=1 colspan=1>Result</td></tr><tr><td rowspan=1 colspan=1>Influenza AWisconsin/67/05 H3</td><td rowspan=1 colspan=1>1.0 x10^{2</td><td rowspan=1 colspan=1>Positive for FLU A</td></tr><tr><td rowspan=1 colspan=1>Influenza A/New Caledonia/10/07 H1N1</td><td rowspan=1 colspan=1>1.0 x10^2</td><td rowspan=1 colspan=1>Positive for FLU A</td></tr><tr><td rowspan=1 colspan=1>Influenza A/Brisbane/10/07 H3</td><td rowspan=1 colspan=1>1.0 x10^{2</td><td rowspan=1 colspan=1>Positive for FLU A</td></tr><tr><td rowspan=1 colspan=1>Influenza A/Solomon Island/03/06 H1</td><td rowspan=1 colspan=1>1.0 x10^{2</td><td rowspan=1 colspan=1>Positive for FLU A</td></tr><tr><td rowspan=1 colspan=1>Influenza A/Taiwan/42/06 H1N1</td><td rowspan=1 colspan=1>1.0 x10^{2</td><td rowspan=1 colspan=1>Positive for FLU A</td></tr><tr><td rowspan=1 colspan=1>Influenza A/Brisbane/59/07 H1</td><td rowspan=1 colspan=1>1.0 x10^{2</td><td rowspan=1 colspan=1>Positive for FLU A</td></tr><tr><td rowspan=1 colspan=1>Influenza A/Swine NY/02/2009 H1</td><td rowspan=1 colspan=1>1.0 x10^{2</td><td rowspan=1 colspan=1>Positive for FLU A</td></tr><tr><td rowspan=1 colspan=1>Influenza AWS/33 H1N1</td><td rowspan=1 colspan=1>1.0 x10^{}</td><td rowspan=1 colspan=1>Positive for FLU A</td></tr><tr><td rowspan=1 colspan=1>Influenza A/Port Chalmers/1/73 H3N2</td><td rowspan=1 colspan=1>1.0 x10^{2</td><td rowspan=1 colspan=1>Positive for FLU A</td></tr><tr><td rowspan=1 colspan=1>Influenza A/California/7/2009 NYMC X-179A</td><td rowspan=1 colspan=1>1.0 x10^2</td><td rowspan=1 colspan=1>Positive for FLU A</td></tr><tr><td rowspan=1 colspan=1>Influenza B/Florida/02/06</td><td rowspan=1 colspan=1>1.0 x10^{2</td><td rowspan=1 colspan=1>Positive for FLU B</td></tr><tr><td rowspan=1 colspan=1>Influenza B/Florida/04/06</td><td rowspan=1 colspan=1>2.0 x10^{}$</td><td rowspan=1 colspan=1>Positive for FLU B</td></tr><tr><td rowspan=1 colspan=1>Influenza B/Florida/07/04</td><td rowspan=1 colspan=1>1.0 x10^{}$</td><td rowspan=1 colspan=1>Positive for FLU B</td></tr><tr><td rowspan=1 colspan=1>Influenza B/Lee/40</td><td rowspan=1 colspan=1>1.0 x10^2</td><td rowspan=1 colspan=1>Positive for FLU B</td></tr><tr><td rowspan=1 colspan=1>Influenza B/Maryland/1/59</td><td rowspan=1 colspan=1>1.0 x10^{2</td><td rowspan=1 colspan=1>Positive for FLU B</td></tr><tr><td rowspan=1 colspan=1>Influenza B/Hong Kong/5/72</td><td rowspan=1 colspan=1>1.0 x10^{2</td><td rowspan=1 colspan=1>Positive for FLU B</td></tr><tr><td rowspan=1 colspan=1>Influenza B/Allen/45</td><td rowspan=1 colspan=1>1.0 x10^{2</td><td rowspan=1 colspan=1>Positive for FLU B</td></tr><tr><td rowspan=1 colspan=1>Influenza B/Taiwan/2/62</td><td rowspan=1 colspan=1>2.0 x10^{2</td><td rowspan=1 colspan=1>Positive for FLU B</td></tr><tr><td rowspan=1 colspan=1>Influenza B/Panama/45/90</td><td rowspan=1 colspan=1>2.0 x10^{2</td><td rowspan=1 colspan=1>Positive for FLU B</td></tr><tr><td rowspan=1 colspan=1>RSV A-Long</td><td rowspan=1 colspan=1>1.0 x10^{2</td><td rowspan=1 colspan=1>Positive for RSV</td></tr><tr><td rowspan=1 colspan=1>RSV B-Wash/18537/62</td><td rowspan=1 colspan=1>1.0 x10^{2</td><td rowspan=1 colspan=1>Positive for RSV</td></tr><tr><td rowspan=1 colspan=1>RSV B-WV/14617/85</td><td rowspan=1 colspan=1>1.0 x10^{2</td><td rowspan=1 colspan=1>Positive for RSV</td></tr><tr><td rowspan=1 colspan=1>RSV B-9320</td><td rowspan=1 colspan=1>1.0 x10^{2</td><td rowspan=1 colspan=1>Positive for RSV</td></tr></table>

# Cross-Reactivity

No cross reactivity was detected for Influenza A, Influenza Bor RSV to organisms that are closely related toinfluenza or RSV, or cause similar clinical symptoms as influenza or RSV, or present as normal flora in the specimen types of interest.

# Interference

The performance of this assay was evaluated with potentiayinterfering substances that may be present in nasoharyngeal was.The potentallyinterfering substances were evaluate in influenza A inflza A/Hong Kong/8/68), and influenza B (influenza B/Malaysia/2506/2004) at a concentration of 50 $T C l D _ { 5 0 } / m L$ and RSV A2 at a concentration of 5 $T C | \textcircled { \scriptsize { \mathsf { D } } _ { 5 0 } / \mathsf { m l } }$ . There was no evidence of interference caused by the substances tested.

# Inhibition by Other Microorganisms

The Splexaasay was evalatey sting heability enty nzavi inlenza s and RSV when potentially inhibitory organisms are present. No inhibitory effects were confirmed for influenza A, influenza B or RSV.

# Clinical Agreement

Thre exteal testing sis participate intheClinical Agrement tudy.Reference results or infuenza an infuza B viruses were generated using a high perfoance FDA cleared nucleic acid test (NAT).Refence results orRSV were generated usig culture/DFA.Culture/DFA results were carid forward from the esults i t hetsaple oletionrbanktoasohayngl swas sees wee from a combination of prospectively collected specimens $( n = 5 5 8 )$ ) from patients with signs and symptoms of viral respiratory tract infection and retrospectively banked specimens from patients with signs and symptoms  viral respiratory tract infection.

Influenza A Clinical Agreement Summary  Prospective Samples   

<table><tr><td rowspan=1 colspan=2>*High Perf. NAT</td><td rowspan=1 colspan=2>Simplexa</td><td rowspan=1 colspan=1>•</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Detected</td><td rowspan=1 colspan=1>NotDetected</td><td rowspan=1 colspan=1>% Agreement</td></tr><tr><td rowspan=1 colspan=1>Detected</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%(25/25)95% CI:86.7-100%</td></tr><tr><td rowspan=1 colspan=1>NotDetected</td><td rowspan=1 colspan=1>528</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>527</td><td rowspan=1 colspan=1>99.8%(527/528)95% CI:98.9-100%</td></tr></table>

<table><tr><td rowspan=1 colspan=2>Culture/DFA</td><td rowspan=1 colspan=2>Simplexa</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Detected</td><td rowspan=1 colspan=1>NotDetected</td><td rowspan=1 colspan=1>Sensitivity /Specificity</td></tr><tr><td rowspan=1 colspan=1>Detected</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%(22/22)95% CI:85.1-100%</td></tr><tr><td rowspan=1 colspan=1>NotDetected</td><td rowspan=1 colspan=1>534</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>530</td><td rowspan=1 colspan=1>99.3%(530/534)95% CI:98.1-99.7%</td></tr></table>

# Influenza B Clinical Agreement Summary - Prospective Samples

<table><tr><td rowspan=1 colspan=2>*High Perf.NAT</td><td rowspan=1 colspan=2>Simplexa</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Detected</td><td rowspan=1 colspan=1>NotDetected</td><td rowspan=1 colspan=1>% Agreement</td></tr><tr><td rowspan=1 colspan=1>Detected</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>50%(1/2)95% CI:9.5-90.5%</td></tr><tr><td rowspan=1 colspan=1>NotDetected</td><td rowspan=1 colspan=1>551</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>550</td><td rowspan=1 colspan=1>99.8%(550/551)95% CI:99-100%</td></tr></table>

<table><tr><td rowspan=1 colspan=2>Culture/DFA.7.     </td><td rowspan=1 colspan=2>•  , Simplexa</td><td rowspan=1 colspan=1>·.</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Detected</td><td rowspan=1 colspan=1>NotDetected</td><td rowspan=1 colspan=1>Sensitivity /Specificity</td></tr><tr><td rowspan=1 colspan=1>Detected</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%(1/1)95% CI:20.7-100%</td></tr><tr><td rowspan=1 colspan=1>NotDetected</td><td rowspan=1 colspan=1>555</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>554</td><td rowspan=1 colspan=1>99.8%(554/555)95% Cl:99-100%</td></tr></table>

RSV Clinical Agreement Summary  Prospective Samples   

<table><tr><td rowspan=1 colspan=2>NAT</td><td rowspan=1 colspan=2>Simplexa</td><td rowspan=1 colspan=1>2     :</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Detected</td><td rowspan=1 colspan=1>NotDetected</td><td rowspan=1 colspan=1>% Agreement</td></tr><tr><td rowspan=1 colspan=1>Detected</td><td rowspan=1 colspan=1>111</td><td rowspan=1 colspan=1>110</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>99.1%(110/111)95% Cl:95.1-99.8%</td></tr><tr><td rowspan=1 colspan=1>NotDetected</td><td rowspan=1 colspan=1>442</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>440</td><td rowspan=1 colspan=1>99.5%(440/442)95% CI:98.4-99.9%</td></tr></table>

<table><tr><td rowspan=1 colspan=2>*Culture/DFA</td><td rowspan=1 colspan=2>Simplexa</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Detected</td><td rowspan=1 colspan=1>NotDetected</td><td rowspan=1 colspan=1>Sensitivity /Specificity</td></tr><tr><td rowspan=1 colspan=1>Detected</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>98</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>98%(98/100)95% CI:93-99.4%</td></tr><tr><td rowspan=1 colspan=1>NotDetected</td><td rowspan=1 colspan=1>455</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>441</td><td rowspan=1 colspan=1>96.9%(441/455)95% CI:94.9-98.2%</td></tr></table>

Influenza A Clinical Agreement Summary  Retrospective Samples   

<table><tr><td rowspan=1 colspan=2>*High Perf.NAT</td><td rowspan=1 colspan=2>Simplexa</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Detected</td><td rowspan=1 colspan=1>NotDetected</td><td rowspan=1 colspan=1>% Agreement</td></tr><tr><td rowspan=1 colspan=1>Detected</td><td rowspan=1 colspan=1>79</td><td rowspan=1 colspan=1>79</td><td rowspan=1 colspan=1>.  0</td><td rowspan=1 colspan=1>100%(79/79)95% CI:95.4-100%</td></tr><tr><td rowspan=1 colspan=1>NotDetected</td><td rowspan=1 colspan=1>98</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>97</td><td rowspan=1 colspan=1>99%(97/98)95% C1:94.4-99.8%</td></tr></table>

<table><tr><td rowspan=1 colspan=2>Culture/DFA</td><td rowspan=1 colspan=2>Simplexa</td><td rowspan=1 colspan=1>EY</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Detected</td><td rowspan=1 colspan=1>NotDetected</td><td rowspan=1 colspan=1>Sensitivity /Specificity</td></tr><tr><td rowspan=1 colspan=1>Detected</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%(80/80)95% CI:95.4-100%</td></tr><tr><td rowspan=1 colspan=1>NotDetected</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>100%(50/50)95% Cl:92.9-100%</td></tr></table>

# Influenza B Clinical Agreement Summary  Retrospective Samples

<table><tr><td rowspan=1 colspan=2>*High Perf.1*&quot;  NAT</td><td rowspan=1 colspan=2>Simplexa</td><td rowspan=1 colspan=1>s S</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Detected</td><td rowspan=1 colspan=1>NotDetected</td><td rowspan=1 colspan=1>% Agreement</td></tr><tr><td rowspan=1 colspan=1>Detected</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%(50/50)95% CI:92.9-100%</td></tr><tr><td rowspan=1 colspan=1>NotDetected</td><td rowspan=1 colspan=1>127</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>127</td><td rowspan=1 colspan=1>100%(127/127)95% Cl:97.1-100%</td></tr></table>

<table><tr><td rowspan=1 colspan=2>Culture/DFA</td><td rowspan=1 colspan=2>ISimplexa</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Detected</td><td rowspan=1 colspan=1>NotDetected</td><td rowspan=1 colspan=1>Sensitivity /Specificity</td></tr><tr><td rowspan=1 colspan=1>Detected</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%(50/50)95% CI:92.9-100%</td></tr><tr><td rowspan=1 colspan=1>NotDetected</td><td rowspan=1 colspan=1>93</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>93</td><td rowspan=1 colspan=1>100%(93/93)95% Cl:96-100%</td></tr></table>

RSV Clinical Agreement Summary - Retrospective Samples   

<table><tr><td rowspan=1 colspan=2>NAT</td><td rowspan=1 colspan=2>Simplexa</td><td rowspan=1 colspan=1>t</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Detected</td><td rowspan=1 colspan=1>NotDetected</td><td rowspan=1 colspan=1>% Agreement</td></tr><tr><td rowspan=1 colspan=1>Detected</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%(22/22)95% CI:85.1-100%</td></tr><tr><td rowspan=1 colspan=1>NotDetected</td><td rowspan=1 colspan=1>155</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>154</td><td rowspan=1 colspan=1>99.4%(154/155)95% Cl:96.4-99.9%</td></tr></table>

High Perf. NAT $=$ High Performance Nucleic Acid Test \*Reference method for clinical performance evaluation for 510(k) clearance.

<table><tr><td rowspan=1 colspan=2>*Culture/DFA</td><td rowspan=1 colspan=2>Simplexa</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Detected</td><td rowspan=1 colspan=1>NotDetected</td><td rowspan=1 colspan=1>Sensitivity /Specificity</td></tr><tr><td rowspan=1 colspan=1>Detected</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%(22/22)95% CI:85.1-100%</td></tr><tr><td rowspan=1 colspan=1>NotDetected</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>96%(24/25)95% CI:80.5-99.3%</td></tr></table>

# Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.

Focus Diagnostics, Inc. c/o Tara Viviani Regulatory Affairs Project Manager 11331 Valley View St. Cypress, California 90630

Re: K102170 Trade/Device Name: Simplexa™ Flu A/B & RSV Regulation Number: 21 CFR $\ S 8 6 6 . 3 9 8 0$ EMP Regulation Name: Respiratory viral panel multiplex nucleic acid assay Regulatory Class: Class II Product Code: OCC Dated: November 11, 2010 Received: November 12, 2010

Dear Ms. Viviani:

We have reviewed your Section $5 1 0 ( \mathbf k )$ premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed

Page 2 - Tara Viviani

predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796- 5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html. Sally A. Hojvat, M.Sc., Ph.D.   
Director   
Division of Microbiology Devices   
Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health

![](images/b963aacd57f78ecf1258ea41226f56df4bce8f332e278c8439a229747c69c36f.jpg)

# Indications for Use

510(k) Number (if known): _K102170_

Device Name: SimplexaTM Flu A/B & RSV

Indications for Use:

The Focus Diagnostics Simplexa™M Flu A/B & RSV assay is intended for use on the 3M Integrated Cycler instrument for the in vitro qualitative detection and discrimination of influenza A virus, influenza B virus, and respiratory syncytial virus (RSV) RNA in nasopharyngeal swabs (NPS) from human patients with signs and symptoms of respiratory tract infection in conjunction with clinical and epidemiological risk factors. This test is intended for use as an aid in the differential diagnosis of influenza A, influenza B, and RSV viral infections in humans and is not intended to detect influenza C.

Negative results do not preclude influenza virus or RSV infection and should not be used as the sole basis for treatment or other patient management decisions.

Performance characteristics for influenza A were established during the 2010 influenza season when 2009 H1N1 influenza was the predominant influenza A virus in circulation. When other influenza A viruses are emerging, performance characteristics may vary.

If infection with a novel Influenza A virus is suspected based on current clinical and epidemiological screening criteria recommended by public health authorities, specimens should be collected with appropriate infection control precautions for novel virulent Influenza viruses and sent to state or local health department for testing. Viral culture should not be attempted in these cases unless a BSL $^ { 3 + }$ facility is available to receive and culture specimens.

Prescription Use _X (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

AND/OR

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED

Concurrence of CDRH, Office of InVitro Diagnostics (OIVD) The Sc Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety 510(k) k102170